Prognostic role of human epidermal growth factor receptor in gastric cancer: A systematic review and meta-analysis

Archives of Medical Research

Volumn 44, Issue 5, 2013, Pages 380-389

  Chen, Cheng ^a   Yang, Jing mo ^a   Hu, Ting ting ^b   Xu, Ting juan ^a   Yan, Guang ^a   Hu, Shi lian ^a   Wei, Wei ^a   Xu, Wei ping ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL CANCER HOSPITAL   (China)

Author keywords

EGFR; Gastric cancer; HER2; Human epidermal growth factor receptor; Meta analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; META ANALYSIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; STOMACH CANCER; SYSTEMATIC REVIEW; METABOLISM; MORTALITY; PROGNOSIS; STOMACH TUMOR;

HUMANS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84883401358     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.07.001     Document Type: Article

References (33)

1. Lavy R., Kapiev A., Poluksht N., et al. Incidence trends and mortality rates of gastric cancer in Israel. Gastric Cancer 2013, 16:121-125.
2. Jing J.J., Liu H.Y., Hao J.K., et al. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol 2012, 18:1262-1269.
3. Dikken J.L., Lemmens V.E., Wouters M.W., et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer 2012, 48:1624-1632.
4. De Vita F., Giuliani F., Silvestris N., et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treatment Rev 2010, 36(suppl 3):S11-S15.
5. Jorissen R.N., Walker F., Pouliot N., et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284:31-53.
6. Liu X., Cai H., Huang H., et al. The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PloS One 2011, 6:e29670.
7. Zhang Y.Z., Zhang L.H., Gao Y., et al. Discovery and validation of prognostic markers in gastric cancer by genome-wide expression profiling. World J Gastroenterol 2011, 17:1710-1717.
8. Jimeno A., Hidalgo M. Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol 2005, 53:179-192.
9. Speake G., Holloway B., Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opinion Pharmacol 2005, 5:343-349.
10. Geng Y.T., Qiu J.R., Wang R., et al. [Expression of HER-2 and leptin in gastric cancer and their clinical significance]. Zhonghua zhong liu za zhi [Chinese J Oncol] 2011, 33:764-769.
11. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
12. Normanno N., Bianco C., De Luca A., et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003, 10:1-21.
13. Hsu J.T., Chen T.C., Tseng J.H., et al. Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist 2011, 16:1706-1713.
14. Xie S.D., Xu C.Y., Shen J.G., et al. HER 2/neu protein expression in gastric cancer is associated with poor survival. Mol Med Rep 2009, 2:943-946.
15. Liakakos T., Xeropotamos N., Ziogas D., et al. EGFR as a prognostic marker for gastric cancer. World J Surg 2008, 32:1225-1226. author reply 27-29.
16. LaBonte M.J., Manegold P.C., Wilson P.M., et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer 2009, 125:2957-2969.
17. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
18. Cervera P., Flejou J.F. Changing pathology with changing drugs: tumors of the gastrointestinal tract. J Immunopathol Mol Cell Biol 2011, 78:76-89.
19. Bamias A., Karina M., Papakostas P., et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010, 65:1009-1021.
20. del Casar J.M., Corte M.D., Alvarez A., et al. Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol 2008, 134:153-161.
21. Iqbal S., Goldman B., Fenoglio-Preiser C.M., et al. Southwest Oncology Group Study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011, 22:2610-2615.
22. Kim C., Lee J.L., Ryu M.H., et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011, 29:366-373.
23. Matsubara J., Yamada Y., Nakajima T.E., et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008, 74:76-83.
24. Moehler M., Mueller A., Trarbach T., et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011, 22:1358-1366.
25. Terashima M., Kitada K., Ochiai A., et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012, 18:5992-6000.
26. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
27. Sawaki A., Ohashi Y., Omuro Y., et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 2012, 15:313-322.
28. Bria E., De Manzoni G., Beghelli S., et al. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 2013, 24:693-701.
29. Janjigian Y.Y., Werner D., Pauligk C., et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012, 23:2656-2662.
30. Tanaka A., Sueoka-Aragane N., Nakamura T., et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 2012, 75:89-94.
31. Li R.K., Qiang O., Liao J., et al. Effects of EGFR inhibitor AG1478 in combination with celecoxib on the growth of gastric cancer cells. Sichuan da xue xue bao Yi xue ban 2010, 41:595-599.
32. Ma B.B., Hui E.P., Mok T.S. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010, 11:75-84.
33. Fornaro L., Lucchesi M., Caparello C., et al. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol 2011, 8:369-383.